comparemela.com

Latest Breaking News On - Lung epicheck - Page 1 : comparemela.com

Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting

Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nucleix Announces Recent Advancements in Early Lung Cancer Detection Program

Nucleix Announces Recent Advancements in Early Lung Cancer Detection Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nucleix announces $22 million in funding, advancements in lung cancer detection program

The Israeli company develops non-invasive, DNA methylation-based cancer screening tests for early-stage and recurring cancer detection

Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients

Share: Data Includes First Real World Evidence on Alternating Bladder EpiCheck® and Cystoscopy for Surveillance of Non-Muscle Invasive Bladder Cancer (NMIBC) Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance, shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance. To alleviate the burden of invasive and costly standard surveillance methods on patients, urine collection was performed at home and shipped to a central lab to perform the Bladder EpiCheck test. In the pi

Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients - Press Release

Data Includes First Real World Evidence on Alternating Bladder EpiCheck® and Cystoscopy for Surveillance of Non-Muscle Invasive Bladder Cancer (NMIBC) Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, “Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance,” shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance. To alleviate the burden of invasive and costly standard surveillance methods on patients, urine collection was performed at home and shipped to a central lab to perform the Bladder EpiCheck test. In the pilot

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.